Immunotherapy for Infectious Diseases

Immunopathogenesis of HIV Disease 161
Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort
Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856–1862.
24. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for
therapy. Science 1993; 262:1011–1018.
25. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during
seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68:5142–5155.
26. Panteleo G, Demarest JF, Soudeys H, et al. Major expansion of CD8 T cells with a predominant
V beta usage during the primary immune response to HIV. Nature 1994;
370:463–467.
27. Mackewicz CE,Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses
in primary HIV-1 infection. Lancet 1994; 344:1671–1673.
28. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis: estimated incidence, prevalence,
and mortality by country. JAMA 1999; 282:677–686.
29. Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Annu
Rev Immunol 1995; 13:487–512.
30. Cullen BR. HIV-1 auxilliary proteins: making connections in a dying cell. Cell 1998;
93:685–692.
31. Rosenberg ES, Walker BD. Characterization of HIV-1 specific T helper cells in acute and
chronic infection. Immunol Lett 1999; 66:89–93.
32. Hellerstein M, Hanley MB, Ktzin BL, et al. Directly measured kinetics of circulating T
lymphocytes in normal and HIV-1 infected humans. Nat Ned 1999; 5:83–89.
33. Douek DC, McFarland RD, Keisre PH, et al. Changes in thymic function with age and during
the treatment of HIV infection. Nature 1998; 396:690–695.
34. Fan J, Bass HZ, Fahey JL. Elevated IFN-gamma and decreased IL-2 gene expression are
associated with HIV infection. J Immunol 1993; 151:5031–5040.
35. Laurence J, Hodtsev A, Posnett DN. Suprantigen implicated in dependence of HIV-1 replication
in T cells on TCR V beta expression. Nature 1992; 58:255–259.
36. Shearer GM. HIV-Induced Immunopathogenesis (review). Immunity 1998; 9:587–593.
37. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in
lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123–F129.
38. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viralload
reduction after highly active antiretroviral therapy in advanced HIV disease. Lancet
1998; 351:1682–1686.
39. Lederman MM, Conick E, Landay A, et al. Immunologic reponses associated with 12
weeks of antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results
of AIDS clinical trials group protocol 315. J Infect Dis 1998; 178:70–79.
40. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of
potent antiretroviral therapy and its relationship to virologic resonse. J Infect Dis 2000;
181:358–363.
41. Giorgi JV, Liu Z, Huitlin LE, et al. Elevated levels of CD38�CD8� T cells in HIV infection
add to the prognostic value of low CD4� T cell levels: results of 6 years of followup.
J Acquir Imm Defic Syndr 1993; 6:904–912.